Results 161 to 170 of about 934,771 (266)
Inclusive Language for Inclusive Care-A Proposal for an LGBTQI<sup>+</sup> Glossary for European Neurologists. [PDF]
Donzuso G +11 more
europepmc +1 more source
Investigating transcription factor dynamics in health and disease using FRAP
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj +3 more
wiley +1 more source
Dataset on criteria for evaluating teaching quality in blended learning environments: Evidence from a Vietnamese university. [PDF]
Nguyen ATT, Tran QX, Tran T, Le L.
europepmc +1 more source
Conserved binding mode but diverse interfaces of MreC‐PBP2 interactions
The crystal structure of abMreC reveals a conserved two β‐barrel architecture and provides structural insights into its role within the bacterial elongasome. The abMreC–abPBP2 complex model identifies the molecular basis of MreC‐mediated PBP2 recognition, contributing to the regulation of peptidoglycan synthesis.
Hyunseok Jang +4 more
wiley +1 more source
FAWPAR at EMOP 2024 and the Special Issue. [PDF]
Djurković-Djaković O +3 more
europepmc +1 more source
Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta +3 more
wiley +1 more source
AI Integration in Spanish Undergraduate Medical Education: National Cross-Sectional Study. [PDF]
Enériz Janeiro A +8 more
europepmc +1 more source
Although too much iron in the brain promotes neurodegeneration, iron ion chelators have had mixed effects in clinical trials. This review explains why; some chelators do not render the iron redox‐inactive (e.g., L1) whereas others do (e.g., desferrioxamine).
Barry Halliwell
wiley +1 more source

